Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its third quarter 2022 financial results on November 3, 2022. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead product, XPOVIO® (selinexor), which is approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets. Investors interested in KPTI should tune in to the call for key financial insights.
- Karyopharm's XPOVIO® is approved in the U.S. for three oncology indications, enhancing revenue potential.
- The company's pipeline targets multiple high unmet need cancer indications, suggesting future growth opportunities.
- None.
-- Conference Call Scheduled for Thursday, November 3, 2022, at 4:30 p.m. ET --
NEWTON, Mass., Oct. 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, November 3, 2022, to discuss the financial results and other company updates.
To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-third-quarter-2022-financial-results-on-november-3-2022-301655315.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will Karyopharm Therapeutics report its third quarter 2022 financial results?
What time is the Karyopharm conference call scheduled for?
What is Karyopharm's lead product?
Where can I access the Karyopharm conference call?
